RBC Capital lowered the firm’s price target on 3M to $78 from $84 and keeps an Underperform rating on the shares. The firm is updating its model following yesterday’s completed spinoff of 3M’s health care business Solventum, the analyst tells investors in a research note. RBC adds that Per- and polyfluoroalkyl substances, or PFAS, litigation will likely be a multi-year overhang for 3M shares while noting that a dividend cut of 50%-70% is coming for the company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMM:
- 3M Settles $10.3B in Water Case, Alongside Healthcare Business Spin-Off
- 3M finalizes settlement with public water suppliers
- 3M invess in hydrogen electrolyzer manufacturer EVOLOH
- 3M to pay $6B through 2029 to resolve Combat Arms Earplug litigation
- Snowflake, MongoDB downgraded to Sell: Wall Street’s top analyst calls
